Dimensional Fund Advisors
ZVRA icon

Dimensional Fund Advisors’s Zevra Therapeutics ZVRA Stock Holding History

Dimensional Fund Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.7M Buy
958,836
+404,034
+73% +$4.49M ﹤0.01% 2180
2026
Q1 		$5.17M Buy
554,802
+400,336
+259% +$3.61M ﹤0.01% 2486
2025
Q4 		$1.38M Buy
+154,466
New +$1.46M ﹤0.01% 2807
2024
Q4 		– Sell
-24,800
Closed -$172K – 3369
2024
Q3 		$172K Sell
24,800
-1,144
-4% -$7.76K ﹤0.01% 3191
2024
Q2 		$127K Hold
25,944
– – ﹤0.01% 3220
2024
Q1 		$150K Sell
25,944
-17,661
-41% -$109K ﹤0.01% 3219
2023
Q4 		$286K Sell
43,605
-10,285
-19% -$48.1K ﹤0.01% 3142
2023
Q3 		$260K Buy
53,890
+8
+0% +$40 ﹤0.01% 3166
2023
Q2 		$275K Hold
53,882
– – ﹤0.01% 3179
2023
Q1 		$296K Buy
+53,882
New +$285K ﹤0.01% 3125
2022
Q3 		$329K Buy
52,722
+1,064
+2% +$6.03K ﹤0.01% 3141
2022
Q2 		$230K Buy
+51,658
New +$235K ﹤0.01% 3233

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors's ZVRA Position: Q2 2026 in Review

Dimensional Fund Advisors increased its Zevra Therapeutics (ZVRA) stake by 73% in Q2 2026, buying an estimated $4.49M and bringing the position to 958,836 shares worth $13.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2180.

Dimensional Fund Advisors first reported a position in ZVRA in Q2 2022 and has held it in 12 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Dimensional Fund Advisors held 958,836 shares of Zevra Therapeutics worth $13.7M as of Q2 2026.
  • Dimensional Fund Advisors bought 404,034 Zevra Therapeutics shares in Q2 2026, an estimated $4.49M.
  • Zevra Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #2180 holding.
  • Dimensional Fund Advisors first reported a position in Zevra Therapeutics in Q2 2022 and has held it in 12 quarters since.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.